José Luis García-Giménez

José Luis García-Giménez (male, Spain), Ph.D., founder and Chief Executive Officer (CEO) of EpiDisease S.L. (The former Spin-Off from the Center for Biomedical Network Research CIBER and Instituto de Salud Carlos III (Spain)). Bachelor in Chemical Science in 2002 and Bachelor in Biochemistry in 2004 (University of Valencia). PhD. Degree in Chemistry in 2007 (University of Valencia). Post-Doctoral fellow in Hake’s lab in Adolf Butenandt Institute, LMU University, Munich (Germany). He holds a position as CIBER’s PhD Researcher since May 2007. Over 12 years of continuous research in 29 funded projects (5 as IP and 24 as collaborator). More than 52 publications in the field of rare diseases, epigenetics, biomarkers, and oxidative stress. Current research collaborations with clinicians and industry. 3 International Patents: 1 Patent in methods for detecting oxidized histones (ES2396387(B1), 1 European patent on miRNAs as biomarkers for AIS diagnosis/prognosis (PCT/EP2016/063935) currently in regional phases (EU, USA, China and Canada) and granted in Europe and 1 European patent on circulating histones as biomarker for sepsis (PCT/EP2017/078362). Member of the International Rare Diseases Research Consortium (IRDiRC). Translational Research Experimental Medicine, and Therapeutics on Charcot-Marie-Tooth Disease (TREAT-CMT). Editor of Translational Epigenetic Series Volume “Epigenetic Biomarkers and Diagnostics” Academic Press Elsevier in 2015. 6 National and international awards.
Participation in Entrepreneurship programs at CaixaImpulse 2018 and MIT LinQ Idea2 Global at Massachussets Institute of Technology in 2016 and 2017 Editions.